241 related articles for article (PubMed ID: 1711604)
1. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
Bowen R; Haslam RJ
J Cardiovasc Pharmacol; 1991 Mar; 17(3):424-33. PubMed ID: 1711604
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
4. Actions of 3-morpholinosydnonimin (SIN-1) on rabbit isolated penile erectile tissue.
Holmquist F; Fridstrand M; Hedlund H; Andersson KE
J Urol; 1993 Oct; 150(4):1310-5. PubMed ID: 8396690
[TBL] [Abstract][Full Text] [Related]
5. Cyclic GMP mediates SIN-1-induced inhibition of human polymorphonuclear leukocytes.
Schröder H; Ney P; Woditsch I; Schrör K
Eur J Pharmacol; 1990 Jul; 182(2):211-8. PubMed ID: 1697805
[TBL] [Abstract][Full Text] [Related]
6. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
Vanderwel M; Haslam RJ
J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
[TBL] [Abstract][Full Text] [Related]
7. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
8. Involvement of platelet cyclic GMP but not cyclic AMP suppression in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro.
Hirafuji M; Nezu A; Shinoda H; Minami M
Br J Pharmacol; 1996 Jan; 117(2):299-304. PubMed ID: 8789382
[TBL] [Abstract][Full Text] [Related]
9. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators.
Grünberg B; Kruse HJ; Negrescu EV; Siess W
J Cardiovasc Pharmacol; 1995 Apr; 25(4):545-51. PubMed ID: 7596121
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins.
Radziszewski W; Chopra M; Zembowicz A; Gryglewski R; Ignarro LJ; Chaudhuri G
Int J Cardiol; 1995 Oct; 51(3):211-20. PubMed ID: 8586470
[TBL] [Abstract][Full Text] [Related]
11. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
12. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost.
Grünberg B; Negrescu E; Siess W
Eur J Pharmacol; 1995 Feb; 288(3):329-33. PubMed ID: 7539769
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS.
Butt E; Pöhler D; Genieser HG; Huggins JP; Bucher B
Br J Pharmacol; 1995 Dec; 116(8):3110-6. PubMed ID: 8719784
[TBL] [Abstract][Full Text] [Related]
14. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
Bult H; Fret HR; Herman AG
J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
[TBL] [Abstract][Full Text] [Related]
15. Effects of activation of protein kinase C on the agonist-induced stimulation and inhibition of cyclic AMP formation in intact human platelets.
Williams KA; Murphy W; Haslam RJ
Biochem J; 1987 May; 243(3):667-78. PubMed ID: 2444206
[TBL] [Abstract][Full Text] [Related]
16. Involvement of cyclic GMP in the mode of action of a new antithrombotic agent PCA-4230; inhibition of the platelet cyclic GMP dependent phosphodiesterase.
Catalán RE; Martínez AM; Aragonés MD; Lombardía M
Thromb Res; 1997 Sep; 87(6):547-57. PubMed ID: 9330437
[TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
Leone RJ; Straznicka M; Scholz PM; Weiss HR
Basic Res Cardiol; 2000 Feb; 95(1):28-38. PubMed ID: 10752543
[TBL] [Abstract][Full Text] [Related]
18. Role of the L-arginine-NO pathway and of cyclic GMP in electrical field-induced noradrenaline release and vasoconstriction in the rat tail artery.
Bucher B; Ouedraogo S; Tschöpl M; Paya D; Stoclet JC
Br J Pharmacol; 1992 Dec; 107(4):976-82. PubMed ID: 1334757
[TBL] [Abstract][Full Text] [Related]
19. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells.
Eigenthaler M; Nolte C; Halbrügge M; Walter U
Eur J Biochem; 1992 Apr; 205(2):471-81. PubMed ID: 1315268
[TBL] [Abstract][Full Text] [Related]
20. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets.
Geiger J; Nolte C; Butt E; Sage SO; Walter U
Proc Natl Acad Sci U S A; 1992 Feb; 89(3):1031-5. PubMed ID: 1310537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
